For M&A diligence on any mRNA, siRNA, or LNP-based company, the critical questions are whether the targets delivery platform is covered by its own patents or depends on third-party technology licenses, whether those licenses are field-limited in a way that constrains the acquirers expansion plans, and whether the targets specific LNP composition is differentiated enough from Modernas and Acuitass patent claims to stand on its own
For his research, Mr
Suzuki T, Heaney LM, Bhandari SS, et al
2) Build a protein anchor you can repeat When appetite is low, consistency beats perfection
Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme
To build the model, only features with less than 30% of subject data missing were used